Title :

Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study.

Author(s) :

Al Hamed, Rama [Auteur]
Albert Einstein College of Medicine [New York]
Ngoya, Maud [Auteur]
CHU Saint-Antoine [AP-HP]
Galimard, Jacques-Emmanuel [Auteur]
CHU Saint-Antoine [AP-HP]
Sengeloev, Henrik [Auteur]
Rigshospitalet [Copenhagen]
Gedde-Dahl, Tobias [Auteur]
Oslo University Hospital [Oslo]
Kulagin, Aleksandr [Auteur]
Pavlov First Saint Petersburg State Medical University [St. Petersburg]
Platzbecker, Uwe [Auteur]
University Hospital Leipzig = Universitätsklinikum Leipzig
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Byrne, Jenny L. [Auteur]
University of Nottingham, UK [UON]
Valerius, Thomas [Auteur]
University Medical Center of Schleswig–Holstein = Universitätsklinikum Schleswig-Holstein [UKSH]
Socie, Gerard [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Kröger, Nicolaus [Auteur]
Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] [UKE]
Blaise, Didier [Auteur]
Institut Paoli-Calmettes [IPC]
Bazarbachi, Ali [Auteur]
American University of Beirut [Beyrouth] [AUB]
Sanz, Jaime [Auteur]
Hospital Universitari i Politècnic La Fe = University and Polytechnic Hospital La Fe
Ciceri, Fabio [Auteur]
Ospedale San Raffaele
Nagler, Arnon [Auteur]
Chaim Sheba Medical Center
Mohty, Mohamad [Auteur]
CHU Saint-Antoine [AP-HP]

Journal title :

Cancer

Abbreviated title :

Cancer

Publication date :

2023-06-04

ISSN :

1097-0142

English keyword(s) :

unrelated donor
transplantation patterns
second complete remission
haploidentical donor
allogeneic transplantation
acute myeloid leukemia

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Background Allogeneic hematopoietic cell transplantation (allo-HCT) is the only cure for acute myeloid leukemia (AML) in second complete remission (CR2). Patients lacking a matched sibling donor (MSD) receive transplants ...
Show more >Background Allogeneic hematopoietic cell transplantation (allo-HCT) is the only cure for acute myeloid leukemia (AML) in second complete remission (CR2). Patients lacking a matched sibling donor (MSD) receive transplants from matched unrelated donors (MUDs), mismatched unrelated donors (MMUDs), haploidentical (haplo) donors, or cord blood. Methods This is a retrospective, registry-based European Society for Blood and Marrow Transplantation study that investigates changes in patient- and transplant-related characteristics and posttransplant outcomes over time. Results We identified 3955 adult patients (46.7% female; median age, 52 years [range, 18–78 years]) with AML in CR2 first transplanted between 2005 and 2019 from a MUD 10/10 (61.4%), MMUD 9/10 (21.9%), or haplo donor (16.7%) and followed for 3.7 years. A total of 725 patients were transplanted between 2005 and 2009, 1600 between 2010 and 2014, and 1630 between 2015 and 2019. Over the three time periods, there was a significant increase in patient age (from 48.7 to 53.5 years; p < .001), use of a haplo donor (from 4.6% to 26.4%; p < .001), and use of posttransplant cyclophosphamide (from 0.4% to 29%; p < .001). There was a significant decrease in total body irradiation and in vivo T-cell depletion. In multivariate analysis, transplants performed more recently had better outcomes. Leukemia-free survival (hazard ratio [HR], 0.79; p = .002) and overall survival (HR, 0.73; p < .001) increased over time. Similarly, nonrelapse mortality (HR, 0.64; p < .001) decreased over time. We also observed better graft-vs-host disease (GVHD) rates (acute GVHD II–IV: HR, 0.78; p = .03; GVHD-free, relapse-free survival: HR, 0.69; p < .001). Conclusions Even in the absence of an MSD, outcomes of allo-HCT in CR2 for AML have significantly improved over time, with most favorable outcomes achieved with a MUD.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-02-06T22:37:36Z
2024-03-22T08:25:08Z